Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

Antiplatelet Effects of Anticoagulants: Potential of Oral Factor Xa Inhibitors to Prevent Arterial Thrombosis
Drug-Eluting Stents in AMI: A Proven Strategy?
Impact of Cilostazol on Platelet Function
Lessons from the ISAR REACT Studies: How Should We Anticoagulate Our Patients for PCI
New Strategies and Devices to Manage Cardiogenic Shock



AMI in the Young

Contemporary data for young Americans presenting with AMI are lacking. Using the National Inpatient sample across ages of 30 to 54 years, investigators found no decline AMI hospitalization rates in those <55 years of age or stratified by sex. Young women with AMI were found to have more comorbidities, longer length of hospital stay, and higher in-hospital mortality.

For more, click here




TAVI-Associated Myocardial Injury

The impact of TAVI upon the myocardial tissue loss is unknown. Using cardiac MRI and myocardial biomarkers, ischemic myocardial injury has been noted in a significant number of patients undergoing TAVI and associated with decreased left ventricular function. The etiology of myocardial injury has been suggested to be embolic.

For more, click here




Time Dependence for Platelet Reactivity

Platelet reactivity testing in response to antiplatelet therapy is usually based upon a single time point. Analysis of data from the ELEVATE-TIMI 56 has suggested that platelet reactivity varies over time in a significant proportion of patients. As a consequence, adjustment of antiplatelet therapy based on a single measurement may lead to erroneous tailoring of therapy.

For more, click here



Untitled Document
Complementary role of percutaneous and surgical circulatory support in cardiogenic shock: Introduction and objectives
- Holger Thiele, MD
How to Solve a Bifurcation Puzzle?: Anatomical, Physiological, and Clinical Relevance of Bifurcation Lesions
- Bon-Kwon Woo, MD, PhD
The Heart Team: Challenges and Strategies for Success
- David J. Cohen, MD, MSc
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study: (the cardiac-RESCUE program)
- Sylvain Beurtheret, MD, et al.
2013 ACS: Year in Review
- Robert P. Giugliano, MD

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

Vinayak Bapat, MDValve in Valve
- Vinayak Bapat, MD
 Click here to visit the WEBEX archives

Trends in Acute Myocardial Infarction in Young Patients and Differences by Sex and Race, 2001 to 2010.
A Gupta, et al.
JACC 2014; 64:337-345
Detection of Myocardial Injury by CMR After Transcatheter Aortic Valve Replacement.
W Kim, et al.
JACC 2014; 64:349-357
Dual-Antiplatelet Treatment Beyond 1 Year After Drug-Eluting Stent Implantation (ARCTIC-Interruption): A Randomised Trial.
J-P Collet, et al.
The Lancet, Early Online Publication, July 16, 2014
Fibroblast Growth Factor-23 and Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).
J Mathew, et al.
Circ 2014; 130:298-307
Efficacy of Long Detection Interval Implantable Cardioverter-Defibrillator Settings in Secondary Prevention Population: Data From the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) Trial.
A Kloppe, et al.
Circ 2014; 130:308-314
Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction.
G Arefalk, et al.
Circ 2014; 130:325-332
Prognostic Significance and Relationship of Worst Lead Residual ST Segment Elevation with Myocardial Damage Assessed by Cardiovascular MRI in Myocardial Infarction.
K Romme, et al.
Heart 2014; 100:1257-1263
Effect of Renin-Angiotensin System Inhibitors on Long-Term Survival in Patients Treated With Beta Blockers and Antiplatelet Agents After Acute Myocardial Infarction (from the MONICA/KORA Myocardial Infarction Registry).
U Amann, et al.
AJC 2014; 114:329-335
Eleven-Year Trends in Gender Differences of Treatments and Mortality in ST-Elevation Acute Myocardial Infarction in Northern Italy, 2000 to 2010.
E Corrada, et al.
AJC 2014; 114:336-341
Nocturnal Patterns of Heart Rate and the Risk of Mortality After Acute Myocardial Infarction.
R Carney, et al.
AHJ 2014; 168:117-125

Poll Archives

G. Guagliumi, MD, et al.
Will preventive intervention outweigh the cardiovascular protection of antithrombotic and lipid-lowering treatment?
M. Valgimigli, MD, PhD
PRAGUE-16 pilot study
Petr Widimsky, MD, et al.
SAPIEN 3 Trial
John Webb, MD
Century II Trial
William Wijns, MD, et al.

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD
The RESOLUTE Program: today and tomorrow
Sigmund Silber, MD, PhD
RESOLUTE International Trial
F-J. Neumann, MD, et al.
Primary Results Following Percutaneous Coronary Intervention with the 38mm Resolute Zotarolimus-eluting Stent
Shirish Hiremath, MD, et al.
Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Small (less or equal to 2.5 mm) Vessels
Ronald Caputo, MD

Boston Scientific Receives CE Mark Approval for 25-mm Lotus TAVR System

Miracor Launches Next-Generation PICSO Impulse System in Europe

FDA Approves Boston Scientific’s Bare-Metal Rebel PtCr Coronary Stent System

Boston Scientific Launches POLARIS™ Imaging System

InspireMD Announces Successful Completion of CGuardTM CARENET (CARotid Embolic protection study using microNET) Trial

Spectranetics Announces Launch of AngioScore’s 200-mm AngioSculpt PTA Scoring Balloon Catheters

BIOTRONIK Announces First Enrollments to BIOFLEX PEACE Registry

Boston Scientific Receives CE Mark For The New 25 mm Lotus™ Valve System

Boehringer Ingelheim’s Investigational Antidote for Pradaxa Receives FDA Breakthrough Therapy Designation

Infraredx Announces the First Patient Enrolled in the PROSPECT II Study on the Detection and Treatment of the Vulnerable Plaques Suspected to Cause Heart Attacks

Spectranetics Completes Acquisition of AngioScore

First European Experience with Innovative Guidewire at St George’s Hospital London, UK

Thoratec Acquires Apica Cardiovascular

The Medicines Company Receives Market Authorization Renewal for Angiox® (Bivalirudin) from the European Medicines Agency and the European Commission

Toshiba’s New Cardiovascular X-ray System Provides Uncompromised Imaging to Meet Facilities’ Clinical Needs

480 Biomedical Awarded $1 Million Phase II NHLBI Contract to Advance Bioresorbable Scaffold for Pediatric Pulmonary Artery Stenosis

Micell Technologies Adds to Portfolio of Intellectual Property Protection
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb